Diagnosis and Tests
Mesenchymal Stromal Cells, Cellular Therapy, and Lupus
Cellular therapy, such as Mesenchymal Stromal Cells, might succeed where other lupus treatments fail...
Lupus Retinopathy and Diagnosis
Retinopathy, damage to the retina, is one of the key early potential...
Frequency Domain Optical Imaging and Lupus Disease Progression
Frequency Domain Optical Imaging is a potential method for diagnosing inflammation-related arthritis in people with SLE. Systemic lupus erythematosus (SLE) is an autoimmune disease, where the body's immune system attacks organs throughout the body. However, SLE's most frequent target is the joints, leading to...
Infectious Processes and Lupus
Infections from pathogens like bacteria, viruses, and fungi are a major issue for people with lupus. They may even serve as a catalyst for symptoms of autoimmunity. Systemic lupus erythematosus, or SLE, is a chronic autoimmune disease with a wide range of symptoms --...
Measuring Lupus Disease Activity Over Time
Some say that the only thing constant is change. This can feel especially true for Lupus Warriors. Despite the value of tracking disease activity, measuring lupus disease activity remains a challenge. Accurate, reliable measurements of disease activity are a crucial element of healthcare and research. Identifying changes in lupus disease...
AI, Machine-Based Learning Software, and Lupus
Will artificial intelligence help us better understand lupus? The answer is yes, through the process of machine learning. (Powered by the correct data of course) “Machine learning” is a term for a type of artificial intelligence or “AI” that adapts and changes how it...
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS for Adult Patients with Active Lupus Nephritis
LUPKYNIS (voclosporin) is the first FDA-approved oral therapy for lupus nephritis, a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death. On Monday, January 25, 2021, Aurinia Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) approved LUPKYNIS (voclosporin) to...
New Lab Test Identifies Lupus Flare Risk 12 Weeks in Advance
New blood test, aiSLE™ DX Flare Risk Index, identifies lupus flare risk up to 12 weeks in advance. The lab test is now available for clinical use. Note: Progentec Diagnostics, Inc., the company that developed aiSLE™ DX Flare Risk Index, also powers LupusCornerLife with lupus comes...
Patient-Reported Outcomes, Quality of Life, and Lupus
Many aspects of lupus can't be recorded with tests. Patient-reported outcomes help Lupus Warriors and researchers better understand the impact of SLE. For Lupus Warriors, trusting your instincts is the way to go. You know the early warning signs of your flares. You know your...
Understanding Lupus Lab Tests & Results
Lupus lab tests provide objective assessments of the goings on within the body. But, reading your lab test results can be confusing. Laboratory tests are an essential part of healthcare. They offer insight into changes within the body that can be measured using biological features. In the old...
Erythrocyte Sedimentation Rate (ESR) and Lupus
This simple blood test doesn’t require a machine – only an hour of waiting on the lab tech’s part. But it can reveal a lot about inflammation in your body, and can help you get closer to a lupus diagnosis. Erythrocyte sedimentation rate tests...